Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $112.5, ...

HealthEquity HQY has faced a challenging start to 2025, with the stock plunging more than ... investors should assess whether future revenue performance justifies the premium, especially given ...

HealthEquity HQY has faced a challenging start to 2025, with the stock plunging more than 13.1% year to date compared with the industry’s 1.5% and S&P 500 Index’s 9.2% decline, respectively. This ...

investors and analysts are closely monitoring its performance and future prospects. According to InvestingPro analysis, HealthEquity’s stock currently appears to be trading near its Fair Value ...

In the fiscal fourth quarter of 2025, HealthEquity demonstrated strong performance with a 19% year ... earnings estimates downward, while the stock has declined about 13.5% in the past week.

HealthEquity, Inc. (NASDAQ:HQY) stock had a great 2024 ... Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether ...

In the fiscal fourth quarter of 2025, HealthEquity demonstrated strong performance with a 19% year-over-year revenue ... recently revised their earnings estimates downward, while the stock has ...

Revenue Growth: HealthEquity's remarkable performance in 3M is evident ... Typically, analysts will rate each stock once a quarter. Beyond their standard evaluations, some analysts contribute ...

HealthEquity fell by 17.07 percent on Wednesday to end at $84.32 each after missing earnings estimates in its latest earnings performance ... are looking for an AI stock that is as promising ...